Nephrology

  • Treating anemia: It’s not just the EPO
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 174-175; DOI: https://doi.org/10.3949/ccjm.89b.04022

    Long-term effects of treatment with the new oral inhibitors of prolyl hydroxylase will need to be carefully monitored, as prolyl hydroxylase is a key structural component of diverse proteins.

  • The devil is in the details: Approach to refractory hypokalemia
    CME article
    Carmen Elena Cervantes, MD, Karthik Meiyappan Udayappan, MD and Duvuru Geetha, MBBS, MD
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 182-188; DOI: https://doi.org/10.3949/ccjm.89a.21013

    The authors illustrate a stepwise approach to the evaluation of acid-base disturbances.

  • Anemia of chronic kidney disease: Will new agents deliver on their promise?
    Anemia of chronic kidney disease: Will new agents deliver on their promise?
    Tarek Souaid, MD, Jonathan Taliercio, DO, James F. Simon, MD, MBA, Ali Mehdi, MD, MEd and Georges N. Nakhoul, MD, MEd
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 212-222; DOI: https://doi.org/10.3949/ccjm.89a.21100

    A review of the pathophysiology of anemia of chronic kidney disease, major clinical trials, and novel therapies.

  • Extraosseous calcification in kidney disease
    Cleveland Clinic Journal of Medicine April 2022, 89 (4) 223;

    The following article in the February 2022 issue contained an error: Bartolomeo K, Tan XY, Fatica R. Extraosseous calcification in kidney disease. Cleve Clin J Med 2022; 89(2):81–90. doi:10.3949/ccjm.89a.21073

  • Extraosseous calcification in kidney disease
    Extraosseous calcification in kidney disease
    CME article
    Korey Bartolomeo, DO, Xin Yee Tan, MD and Richard Fatica, MD
    Cleveland Clinic Journal of Medicine February 2022, 89 (2) 81-90; DOI: https://doi.org/10.3949/ccjm.89a.21073

    A review of the pathogenesis, presentation, diagnosis, and treatment of vascular and soft tissue calcifi cation.

  • SGLT-2 inhibitors are potential game-changers (for more than diabetes)
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine November 2021, 88 (11) 588-589; DOI: https://doi.org/10.3949/ccjm.88b.11021

    Data from large clinical trials and improved understanding of the biologic effects of these drugs are changing expectations for the clinical course in patients with diabetes, as well as chronic kidney disease and heart failure.

  • SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation
    CME article
    Enrico G. Ferro, MD, Bertram Pitt, MD and Deepak L. Bhatt, MD, MPH
    Cleveland Clinic Journal of Medicine November 2021, 88 (11) 601-606; DOI: https://doi.org/10.3949/ccjm.88a.21045

    SGLT-2 inhibitors remain vastly underused in clinical practice despite their broad cardiorenal benefits.

  • Can I place a peripherally inserted central catheter in my patient with chronic kidney disease?
    Nora Hilda Hernandez Garcilazo, MD, Mohamed Hassanein, MD, Tushar J. Vachharajani, MD and Evamaria Anvari, MD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 431-433; DOI: https://doi.org/10.3949/ccjm.88a.20173

    Future need for permanent dialysis access is an important consideration.

  • How do you effectively evaluate the elderly for alcohol use disorder?
    Moronkeji Fagbemi, MD, FASAM
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 434-439; DOI: https://doi.org/10.3949/ccjm.88a.20123

    A brief review of clues to an underrecognized and underdiagnosed problem with physical as well as emotional and social consequences.

  • The obesity paradox in heart failure: What is the role of cardiorespiratory fitness?
    Asad Khan, MD, Erik H. Van Iterson, PhD and Luke J. Laffin, MD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 449-458; DOI: https://doi.org/10.3949/ccjm.88a.20098

    What should these patients be advised about weight management and about cardiorespiratory fitness, a major factor influencing the paradox?

Pages